IGF-1 LR3

IGF-1 LR3 (Long R3 IGF-1) is a laboratory-engineered version of insulin-like growth factor 1 (IGF-1), a hormone the body normally produces in response to growth hormone. It was created as a cell-culture research reagent — not as a human drug candidate — because its modifications make it bind poorly to the proteins that normally deactivate IGF-1, so it stays active longer and appears more potent in lab settings. It has never been tested in human clinical trials for any therapeutic use. Despite this, it is widely sold as an unapproved “research peptide” and used off-label in bodybuilding communities, where dosing information comes entirely from vendor sites and forums rather than any clinical or even animal-safety literature specific to human use.

Research snapshot

Peptide category	Laboratory-engineered analogue of insulin-like growth factor 1 (IGF-1); originally a cell-culture research reagent
Primary research interest	Muscle growth/anabolic effect (marketed off-label; not established in human trials)
Highest available evidence	Tier 4 — laboratory/cell-culture and some animal research; no human clinical or even animal-safety literature specific to this off-label human use
Human research available	No — never tested in human clinical trials for any therapeutic use
Development status	Not developed as a human drug candidate; created as a cell-culture research reagent
Regulatory status	Never submitted for or granted approval by the FDA, EMA, or any comparable regulatory body; sold as a research-grade reagent and separately as an unregulated compound for off-label human use

Technical identity

Primary name	IGF-1 LR3 (Long R3 IGF-1)
Alternative names	Long R3 IGF-1
Peptide sequence	Not independently re-verified in this pass — described as native IGF-1 with 13 additional amino acids at the N-terminus plus an arginine-for-glutamic-acid substitution at position 3 (the source of “R3” in its name)
Amino-acid length	Not independently re-verified in this pass (native IGF-1 is 70 residues; LR3 adds 13 more)
Molecular formula	Not independently re-verified in this pass
Molecular weight	Not independently re-verified in this pass
CAS Registry Number	Not independently re-verified in this pass
PubChem CID	Not independently re-verified in this pass
Chemical modifications	N-terminal 13-residue extension plus Arg3 substitution, engineered to reduce binding to IGF-binding proteins so the molecule remains active longer in vitro
Peptide class	Insulin-like growth factor analogue
Primary biological target	IGF-1 receptor
Developer or originator	Laboratory/academic research reagent; not developed by a named commercial drug sponsor
Development status	Not in human drug development; sold as a research chemical

What is IGF-1 LR3?

IGF-1 LR3 is a modified, longer version of insulin-like growth factor 1 (IGF-1), a natural hormone that the liver and other tissues produce mainly in response to growth hormone, and that plays a central role in cell growth, tissue repair, and metabolism throughout the body. Native human IGF-1 is a 70-amino-acid protein. IGF-1 LR3 is an 83-amino-acid analog: it has an extra 13 amino acids added to its front end, and a single amino acid substitution (an arginine in place of glutamic acid at position 3 of the original IGF-1 sequence, which is where the “R3” in its name comes from).

These changes were not made to create a human medicine. IGF-1 LR3 was developed as a laboratory tool, primarily for cell-culture and biotechnology research, because the modifications drastically reduce its binding to IGF-binding proteins (IGFBPs) — proteins that normally latch onto circulating IGF-1 and limit how much of it is biologically active at any given time. With much lower IGFBP binding, IGF-1 LR3 remains active in solution and in cell-culture systems far longer than native IGF-1, and is reported to be several times more potent in receptor-activation assays as a result — not because the underlying hormone signal is stronger, but because more of it stays “free” and available to act on the receptor.

Because of this profile, IGF-1 LR3 has been used mainly as a cell-culture supplement in biotech and research laboratories, and has not been developed or tested as a therapeutic drug in humans. There is no record of it undergoing human clinical trials, no approved medical indication, and no pharmaceutical company development history comparable to an actual investigational drug. Its presence today is almost entirely as an unregulated compound sold through peptide and “research chemical” vendors, marketed to bodybuilders and enthusiasts for muscle growth and fat loss, well outside its original research-tool purpose.

How does it work?

Plain-English explanation

IGF-1 normally acts like a growth signal that tells cells, especially muscle cells, to take in nutrients and grow. IGF-1 LR3 is built to act like IGF-1 but stick around longer in the body or in a lab dish, because it slips past the proteins that would normally soak it up and deactivate it. In theory, this means more of the growth signal stays active for longer. In practice, this same property is exactly why it raises safety concerns for use in a whole living person rather than an isolated tissue sample — the normal binding proteins exist in the body for a reason, partly to limit runaway or uncontrolled IGF-1 signaling, including its effect on blood sugar.

Technical explanation

IGF-1 LR3 is an IGF-1 receptor (IGF-1R) agonist. Its N-terminal 13-residue extension and Arg3-for-Glu3 substitution sharply reduce affinity for IGF binding proteins (IGFBP-1 through IGFBP-6), which in the native hormone sequester the great majority of circulating IGF-1 and regulate its bioavailability. Reduced IGFBP binding increases the free, receptor-available fraction of the molecule and extends its functional half-life relative to native IGF-1 (roughly 20-30 hours reported for IGF-1 LR3 versus roughly 12-15 hours for native IGF-1), which is the basis for its “long-acting” and “more potent” reputation in cell-based assays. IGF-1R activation triggers PI3K/Akt and MAPK signaling pathways that drive protein synthesis, cell proliferation, and glucose uptake — the last of which is mechanistically linked to the hypoglycemia risk associated with this class of compound.

Potential benefits and research applications

Cell-culture and laboratory research tool (laboratory/mechanistic evidence)

What is being investigated: using IGF-1 LR3 as a stable, long-lasting IGF-1R agonist in cell-culture media for growth-factor research, particularly in serum-free or low-protein culture systems where IGFBP interference would otherwise blunt signaling. How the effect might occur: reduced IGFBP binding keeps more of the compound bioavailable to activate the IGF-1 receptor in vitro. Evidence: this is IGF-1 LR3’s original and best-supported use, documented in cell-biology and biotechnology literature. Strength: well established as a laboratory reagent. Limitation: laboratory cell-culture behavior does not establish safety or efficacy for use in a living human body, where systemic IGFBP regulation, blood glucose control, and tissue-specific effects are far more complex than a culture dish.

Muscle growth and localized hypertrophy claims (community-reported, unestablished)

What is being investigated: claims, mainly from bodybuilding communities, that injecting IGF-1 LR3 directly into or near a specific muscle can produce localized muscle growth in that area. How the effect might occur: theoretically through local IGF-1R activation driving satellite cell proliferation and protein synthesis in nearby muscle tissue. Evidence: has been reported anecdotally; this session did not identify controlled human research supporting site-specific “spot growth” claims for IGF-1 LR3. Strength: has not been established. Limitation: no peer-reviewed human trial evaluating IGF-1 LR3 for localized or general muscle hypertrophy in healthy adults was identified.

Fat loss and body-composition claims (community-reported, unestablished)

What is being investigated: claims that IGF-1 LR3 improves body composition or accelerates fat loss when used alongside training and dieting. How the effect might occur: IGF-1 signaling has some role in metabolism and nutrient partitioning generally, but this is a broad physiological association, not evidence specific to IGF-1 LR3 dosing in humans. Evidence: anecdotal, community-reported only. Strength: has not been established. Limitation: no controlled human data exists for this specific compound and this specific claim.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Amounts studied in human research

No established or reliably sourced dosing information was identified. This session found no record of IGF-1 LR3 having been tested in a published human clinical trial at any dose, for any purpose. Any specific human dosage figure attached to IGF-1 LR3 online does not come from clinical research.

Amounts studied in animal research

Not consistently reported. IGF-1 LR3 has been used in some laboratory animal and cell-based research contexts related to IGF-1 receptor signaling, but a consolidated, independently verifiable set of animal dosing figures specific to IGF-1 LR3 was not identified in this research pass.

Practitioner and community-reported protocols

Bodybuilding and peptide-vendor sources widely describe IGF-1 LR3 doses in the range of roughly 20 to 50 micrograms per day, typically injected subcutaneously or intramuscularly, sometimes described as being injected near a specific muscle group for the claimed “localized growth” effect, and often used for short cycles (commonly described as around 4 to 6 weeks) due to concerns raised within these same communities about receptor downregulation and hypoglycemia risk with longer use. This 20-50 mcg/day range is widely repeated across vendor and forum content, but its original source could not be verified, and it does not trace back to any published clinical or even formal animal-safety study. Community sources consistently flag hypoglycemia (low blood sugar) as a specific practical risk of this compound and describe monitoring blood sugar or eating around injections as a self-management practice, which itself underscores that this is unsupervised, non-clinical use.

Side effects, risks, and limitations

Because IGF-1 LR3 has not been through human clinical development, there is no formal, systematically collected human safety data for it. The most consistently reported concern, both mechanistically and anecdotally within user communities, is hypoglycemia (dangerously low blood sugar), since IGF-1 receptor activation increases glucose uptake into tissue, similar in effect to insulin. Community reports also describe potential organ growth concerns with prolonged or high-dose use, based on general concerns about unregulated IGF-1 axis activity, though this session did not find controlled human data confirming or quantifying this risk for IGF-1 LR3 specifically. As with any unregulated peptide sold through research-chemical channels, additional risks apply regardless of the molecule’s pharmacology: unverified purity, unverified concentration, contamination, and unsterile compounding are recognized general risks with unregulated injectable peptides and have not been evaluated for any specific vendor supply of IGF-1 LR3.

Regulatory and developmental status

IGF-1 LR3 has never been submitted for or granted approval as a human drug by the FDA, EMA, or any comparable regulatory body, and there is no public record of it having entered human clinical trials. It exists commercially mainly as a research-grade biochemical reagent intended for laboratory and cell-culture use, and separately as an unregulated compound sold through peptide vendors for off-label human self-administration, which falls outside any approved medical or dietary-supplement framework in the United States.

Frequently asked questions

What is IGF-1 LR3?

IGF-1 LR3 is a laboratory-modified, longer-acting version of the natural hormone IGF-1, created as a cell-culture research tool rather than as a human drug. It resists deactivation by the body’s IGF-binding proteins, which makes it act more potently in lab settings.

How does IGF-1 LR3 work?

It activates the IGF-1 receptor much like natural IGF-1 does, but its structural modifications reduce how strongly it binds to IGF-binding proteins, so more of it stays biologically active for a longer period of time.

What dosage has been studied in humans?

No established or reliably sourced dosing information was identified. IGF-1 LR3 has not been tested in published human clinical trials.

What dosage commonly circulates online?

Bodybuilding and vendor sources widely describe roughly 20 to 50 micrograms per day, injected subcutaneously or intramuscularly. This figure is widely repeated but its original source could not be verified, and it does not come from any clinical study.

Has IGF-1 LR3 been studied in humans?

No. This session found no record of IGF-1 LR3 undergoing formal human clinical trials for any purpose. It has been used mainly as a research-laboratory cell-culture reagent.

What side effects have been reported?

Hypoglycemia (low blood sugar) is the most consistently mentioned risk, both mechanistically and anecdotally, because activating the IGF-1 receptor increases glucose uptake similarly to insulin. Long-term human safety data does not exist for this compound.

Is IGF-1 LR3 approved for use?

No. It has never been approved as a drug and is not legally sold as a dietary supplement. It is used off-label as an unregulated research chemical.

Does IGF-1 LR3 cause “localized” muscle growth when injected near a muscle?

This claim has been reported anecdotally in bodybuilding communities but has not been established in controlled human research.

What remains unknown about IGF-1 LR3?

Essentially all questions about human dosing, efficacy, and long-term safety remain unanswered by controlled research, since IGF-1 LR3 has never undergone formal human clinical study.

Bottom line

IGF-1 LR3 is a real, well-characterized laboratory analog of IGF-1 with a clear and well-documented purpose in cell-culture research. It has no history of human clinical development, no approved medical use, and no controlled human safety or dosing data of any kind. Everything circulating about IGF-1 LR3 for muscle building or fat loss in bodybuilding communities — including the widely repeated 20-50 mcg/day dosing figure — comes from unsupervised self-experimentation and vendor marketing, not from clinical or even formal preclinical human-relevant research, and the mechanistic hypoglycemia risk associated with IGF-1 receptor activation should be weighed accordingly.